What Are The Aspects of Growth In Epigenetics Market?
                     MarketsandMarkets 
Presents
Epigenetics Market worth $3.9 billion by 2027
https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.
html
The report "Epigenetics Market was valued at USD 1.7 billion in 2022 and is expected to reach 
USD 3.9 billion by 2027 at a CAGR of 18.1% during the forecast period.
Browse 270 market data Tables and 39 Figures spread through 248 Pages and in-depth TOC on 
"Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents 
(Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), 
Application (Oncology, Immunology), End User - Global Forecast to 2027“
The demand for epigenetic enzymes has elevated significantly over the years, particularly in drug 
discovery and development. In addition, advancements technologies targeted towards 
epigenetic analysis supplements this increased demand. Moreover, robust funding and 
investment in epigenetics market, especially in PCR and NGS segments is expected to propel 
market growth. The pace of R&D in innovative genetic technologies and epigenetics product 
development has increased over the years, attributed to the high investments in turn driving the 
market growth. However, variability within the reference epigenomes in heterogeneous sample 
groups makes it difficult to employ epigenetics solutions in toxicology studies. This is expected to 
restraint the market growth to a certain extent.
Download a PDF Brochure: https://www.marketsandmarkets.com/
Objectives of the Study:
• The kits & reagents segment dominated
Based on product & service, the global epigenetics market is segmented into kits & 
reagents, enzymes, instruments and accessories, software, and service. Antibodies 
is the highest revenue contributor of this segment, increasing adoption of antibodies 
in detection, identification, and alteration/modification of proteins followed by their 
role in monitoring cell regulation & expression, driving the segment growth. Broad 
applications of antibodies in epigenetics research across different techniques such 
as, immunofluorescence, western blotting, and ChIP has propelled various market 
players to expand their product offerings around traditional as well as recombinant 
antibodies.
• The DNA methylation segment has accounted for the highest share
• The cardiovascular diseases segment is expected to register the highest growth
• Asia Pacific has registered fastest growth rate
Speak to Analyst: https://www.marketsandmarkets.com/
This report categorizes the epigenetics market into the following 
segments
By Product & Service
• Kits & Reagents
• Enzymes
• Instruments and Accessories
• Software
• Service
By Method
• DNA Methylation
• Histone Modifications
• Other Methods
By Application
• Oncology
• Metabolic Diseases
• Immunology
• Developmental Biology
• Cardiovascular Diseases
By End User
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
The epigenetics market is moderately consolidated with prominent players operating in 
this market such as Thermo Fisher Scientific, Merck KGaA, Illumina, Inc., PacBio, Abcam 
plc, Active Motif, Inc., Bio-Rad Laboratories, Promega Corporation, PerkinElmer, Qiagen, 
New England Biolabs, Zymo Research Corporation, Diagenode, and F. Hoffmann-La 
Roche Ltd and Among Others
Companies Insight
Illumina, Inc. (US) accounted for the largest share in the epigenetics market in 2021. Illumina, 
Inc. is one of the prominent companies engaged in developing array-based solutions and 
sequencing products targeted towards genetic applications. The company has been able to build 
a strong customer base, which spans across pharmaceutical & biotechnology companies, 
genomic research centers, and government laboratories & hospitals. Additionally, Illumina 
exhibits monopoly in the NGS market, which offers the company a competitive edge to enter the 
adjacent markets like epigenetic sequencing.
Thermo Fisher Scientific (US) ranked second in the epigenetics market in 2021. Strong brand 
image of the company along with the diverse product portfolio is attributive to the company’s 
share in the epigenetics market. Life Science has been a strong source of revenue stream for 
Thermo Fisher Scientific through 2019 to 2021, the company offers epigenetics solutions 
through its Life Science business segment. The acquisition of Life Technologies allowed it to 
develop advanced solutions for functional analysis assays, sample preparation, sequencing, and 
quantitative PCR (qPCR). Its diverse offers have strengthened its presence in epigenetics 
research.
Merck KGaA (Germany) accounted for the third-largest share in the epigenetics market revenue 
in 2021. The company offers an array of epigenetics assays and kits through the Life Science 
Research business segment, which accounted for more than 45% of the company’s revenue 
generated in 2021. 
Contact Us
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road, Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
Press release: 
https://www.marketsandmarkets.com/PressReleases/epigenetics-tec
hnologies.asp
Research insights: 
https://www.marketsandmarkets.com/ResearchInsight/epigenetics-te
chnologies-market.asp
About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche 
opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. 
Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 
companies as clients. Almost 75,000 top officers across eight industries worldwide 
approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high 
growth markets following the "Growth Engagement Model – GEM". The GEM aims at 
proactive collaboration with the clients to identify new opportunities, identify most 
important customers, write "Attack, avoid and defend" strategies, identify sources of 
incremental revenues for both the company and its competitors. MarketsandMarkets™ 
now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, 
emerging companies, innovators, strategic players) annually in high growth emerging 
segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies 
this year for their revenue planning and help them take their innovations/disruptions 
early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, 
"RT" connects over 200,000 markets and entire value chains for deeper understanding 
of the unmet insights along with market sizing and forecasts of niche markets.